Brainstorm Cell Therapeutics Inc. (BCLI) vs Lexaria Bioscience Corp. (LEXX)

Brainstorm Cell Therapeutics Inc. and Lexaria Bioscience Corp. are both Biotechnology companies. Brainstorm Cell Therapeutics Inc. and Lexaria Bioscience Corp. are of similar size ($7.1M and $7.0M). Across the 10 metrics below, Brainstorm Cell Therapeutics Inc. leads on 7 and Lexaria Bioscience Corp. on 3.

Valuation

Metric BCLI LEXX Biotechnology median
P/E n/m n/m 7.88
P/S n/m 10.01 11.47
P/B n/m 1.25 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 3.66 10.73
Earnings yield (97.01%) (155.41%) (28.84%)
Free cash flow yield (38.35%) (138.70%) (23.03%)

Profitability

Metric BCLI LEXX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 119.20% (162.60%) (57.72%)
Return on assets (627.43%) (134.20%) (49.22%)
Return on invested capital 0.00% (662.56%) 0.00%

Growth

Metric BCLI LEXX Biotechnology median
Revenue growth (TTM) — 9.08% 5.64%
EPS growth (last fiscal year) 51.95% (40.43%) —
Revenue growth, 5-year CAGR — 17.53% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCLI LEXX Biotechnology median
Debt to equity (0.11) 0.00 0.00
Current ratio 0.03 10.60 4.73
Net debt to EBITDA (0.10) 0.17 0.96

Dividend

Metric BCLI LEXX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BCLI LEXX Biotechnology median
Market cap 6.99m 7.10m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack